CARsgen Therapeutics Companies
CARsgen Therapeutics is a leading immunotherapy company focused on the development of new chimeric antigen receptor T (CAR-T) cell therapeutics for liver, lung, stomach, and brain cancers. They have partnerships with the Shanghai Cancer Institute and Shanghai Renji Hospital. CARsgen has achieved significant milestones in CAR-T development, including completing the world's first hepatocellular carcinoma (HCC) and China's exclusive glioblastoma multiforme (GBM) dose ascending injection tests. With funding from BVCF, a leading venture capital firm, CARsgen is well-positioned to bring novel cancer therapeutics to the market in China and worldwide. Their mission is to provide innovative and differentiated cell therapies for cancer patients worldwide and make cancer curable.
